Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Clinical genitourinary cancer - 1 Sept 2013

Figg William D, Chau Cindy H, Madan Ravi A, Gulley James L, Gao Rui, Sissung Tristan M, Spencer Shawn, Beatson Melony, Aragon-Ching Jeanny, Steinberg Seth M, Dahut William L

Abstract excerpt

BACKGROUND: We assessed the effect of excision repair cross-complementing group 1 (ERCC1) and x-ray cross-complementing group 1 (XRCC1) gene polymorphisms on treatment outcomes with satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. PATIENTS AND METHODS: Twenty-four patients were enrolled in this single arm study. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Organoplatinum Compounds

Share to Prednisone

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Share to X-ray Repair Cross Complementing Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 23684781
DOI: 10.1016/j.clgc.2013.04.007
PMCID: PMC3758779

Genes

XRCC1
ERCC1

Variants

rs11615
rs11615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.PMID 23684781Read ↗

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.Semantic proximity Read ↗

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Semantic proximity Read ↗

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study ResultsSemantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.Semantic proximity Read ↗

The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.Semantic proximity Read ↗

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.Semantic proximity Read ↗

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.Semantic proximity Read ↗

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.